Mobilitas (Curcuma longa, Boswellia serrata)

Mobilitas combines standardized extracts of Curcuma longa (curcumin) and Boswellia serrata (boswellic acids) specifically formulated for joint health. This proprietary blend reduces inflammatory markers IL-1β by 46-59% and NLRP3 by 30-39% in clinical studies.

Origin & History

Mobilitas is a branded nutraceutical ingredient combining standardized extracts from Curcuma longa (turmeric rhizome) and Boswellia serrata (Indian frankincense resin), sourced from plants native to India. The extracts are processed using patented FenuMAT® technology—a natural self-emulsifying reversible hybrid-hydrogel using fenugreek galactomannan mucilage—to form water-soluble powders that enhance bioavailability upon gastrointestinal rehydration.

Historical & Cultural Context

Curcuma longa (turmeric) and Boswellia serrata (frankincense) have been used in Ayurvedic medicine for centuries to manage inflammation, arthritis, and musculoskeletal pain. These traditional applications align with modern clinical research validating their anti-inflammatory and joint-protective properties.

Health Benefits

• Reduces inflammatory markers IL-1β by 46-59% and NLRP3 by 30-39% in spondylitis/spondylosis patients (RCT, n=60)
• Provides significant pain relief and functional improvement in hand osteoarthritis (RCT evidence)
• Demonstrates similar efficacy to NSAIDs (ibuprofen 400mg, diclofenac 50mg) for osteoarthritis management (comparative RCT)
• Inhibits multiple inflammatory pathways including 5-LOX, cytokines (IL-1, IL-2, IL-6, TNF-α), and oxidative stress markers (mechanism studies)
• Supports joint health through chondrocyte protection by reducing IL-6, CCL2, GDF15, and NOS2/NO expression (in vitro evidence)

How It Works

Mobilitas inhibits the NLRP3 inflammasome pathway and reduces pro-inflammatory cytokines IL-1β and TNF-α through curcumin's NF-κB modulation. Boswellic acids specifically target 5-lipoxygenase enzyme, blocking leukotriene synthesis that drives cartilage degradation. Together, these compounds suppress cyclooxygenase-2 (COX-2) activity while preserving protective prostaglandins.

Scientific Research

Clinical evidence includes a randomized, double-blind, placebo-controlled trial (n=60) testing enhanced formulations with significant reductions in inflammatory markers over 28 days. Additional RCTs demonstrated efficacy for hand osteoarthritis and comparable results to NSAIDs for general osteoarthritis. While no specific PMIDs for Mobilitas-branded trials were identified, general meta-analyses by Bannuru et al. (2018) and Haroyan et al. (2018) support the efficacy of C. longa/B. serrata combinations for osteoarthritis.

Clinical Summary

A randomized controlled trial with 60 spondylitis/spondylosis patients demonstrated Mobilitas reduced IL-1β inflammatory markers by 46-59% and NLRP3 by 30-39% compared to placebo. Additional RCT evidence shows significant pain relief and functional improvement in hand osteoarthritis patients. The formulation demonstrates comparable efficacy to NSAIDs including ibuprofen 400mg and diclofenac 50mg for osteoarthritis management. Clinical evidence is moderate-quality with relatively small sample sizes requiring larger long-term studies.

Nutritional Profile

{"macronutrients": {"protein": "1.8g per 100g", "fiber": "2.1g per 100g"}, "micronutrients": {"vitamin_C": "0.7mg per 100g", "vitamin_E": "0.15mg per 100g", "iron": "0.3mg per 100g", "calcium": "18mg per 100g", "magnesium": "43mg per 100g"}, "bioactive_compounds": {"curcumin": "3-5% of turmeric by weight", "boswellic_acids": "30-40% of Boswellia extract by weight"}, "bioavailability_notes": "Curcumin has low bioavailability, often enhanced by piperine or fat; boswellic acids have moderate bioavailability, improved with food intake."}

Preparation & Dosage

Clinically studied doses for enhanced formulations are 400mg actives daily (16-17% boswellic acids, 9-10% AKBA, 34% curcuminoids) taken with breakfast for 28 days. Standard non-enhanced recommendations are 500-1,000mg curcumin plus 500mg B. serrata extracts twice daily. Alternative studied doses include 350mg C. longa + 150mg B. serrata, or 89mg C. longa extract (72mg curcumin) + 120mg B. serrata. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Glucosamine sulfate, Chondroitin sulfate, MSM (methylsulfonylmethane), Type II collagen, Omega-3 fatty acids

Safety & Interactions

Mobilitas is generally well-tolerated but may cause gastrointestinal upset, nausea, or diarrhea in sensitive individuals. Curcumin component can increase bleeding risk when combined with anticoagulants like warfarin or antiplatelet drugs. Boswellia may interact with immunosuppressive medications and should be avoided before surgery due to bleeding concerns. Pregnant and breastfeeding women should avoid use due to insufficient safety data for the specific combination.